Kevin J. Filipski

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 114 citations · Full text

Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle

Jeffrey A. Pfefferkorn, Jihong Lou, Martha L. Minich et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 80 citations · Full text

Unique Metabolic Liability, Biochemistry, Medicine +10

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations

A versatile copper-catalyzed coupling reaction of pyridin-2(1H)-ones with aryl halides

Kevin J. Filipski, Jeffrey T. Kohrt, Agustin Casimiro‐Garcia et al. · Tetrahedron Letters · 2006 · 56 citations

Aryl Halides, Chemical Engineering, Cross-coupling Reaction +7

Novel and selective spiroindoline-based inhibitors of sky kinase

Noel A. Powell, Jeffrey T. Kohrt, Kevin J. Filipski et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 48 citations · Full text

Medicinal Chemistry, Pharmaceutical Chemistry, Medicine +6